Baseline patient characteristics of randomised controlled trials included in the meta-analysis.

<p>MACEs was defined as cardiac death, recurrent myocardial infarction, and target vessel or lesion revascularization. EES  =  everolimus-eluting stents. IVUS  =  intravascular ultrasound; LAD  =  left anterior descending artery; LCX  =  left circumflex artery; LM  =  left main artery; MACEs  =  major adverse cardiac events; NA  =  not available; NIT  =  neointimal thickness; NSTEACS  =  non-ST-segment elevation acute coronary syndrome; OCT  =  optical coherence tomography; PES  =  paclitaxel-eluting stents. RCA  =  right coronary artery; SES  =  sirolimus-eluting stents; STEAMI  =  ST-segment elevation acute myocardial infarction; ZES  =  zotarolimus-eluting stent.</p

Flow chart of studies selection.

<p>DES  =  drug-eluting stents; RCTs  =  randomized controlled trials; FDA  =  the US Food and Drug Administration.</p

Baseline lesion and procedural characteristics.

<p>DAPT  =  dual antiplatelet therapy; NA  =  not available; TIMI  =  Thrombolysis In Myocardial Infarction.</p

Pooled risk ratios of second-generation versus first-generation drug-eluting stents for acute coronary syndrome for recurrent myocardial infarction (A), target lesion revascularization (B), and definite or probable stent thrombosis (C).

<p>Abbreviations as <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072895#pone-0072895-g002" target="_blank">Figure 2</a>.</p

Subgroup analyses based on the data on MACEs, TLR, and stent thrombosis.

<p>ACS  =  acute coronary syndrome; AMI  =  acute myocardial infarction; CI  =  confidence intervals; EES  =  everolimus-eluting stents; MACEs  =  major adverse cardiac events; RR  =  risk ratios; TIMI  =  Thrombolysis In Myocardial Infarction; TLR  =  target lesion revascularization; ZES  =  zotarolimus-eluting stent.</p

Characteristics of studies included in the meta-analysis.

<p>PCR-RFLP: Polymerase chain reaction-restriction fragment length polymorphism.</p

Forest plots of all studies and studies with Asian samples under different genetic models.

<p><b>a</b>. All studies (Additive model). <b>b</b>. Studies with Asian samples (Additive model). <b>c</b>. Studies with Asian samples (Recessive model). <b>d</b>. Studies with Asian samples (Dominant model).</p

Flow chart of selection of studies and specific reasons for exclusion from the meta-analysis.

<p>Flow chart of selection of studies and specific reasons for exclusion from the meta-analysis.</p

Genotype frequencies of <i>CYP2A6*4</i> in studies included in the meta-analysis.

a<p>Absolute number of patients; ^b Absolute number of controls; ^c HWE: Hardy-Weinberg equilibrium, which was evaluated using the goodness-of-fit chi-square test. P < 0.05 was considered representative of a departure from HWE.</p

Pooled odds ratio for <i>CYP2A6*4</i> in meta-analyses.

a<p>Random-effects model was used when the p-value for heterogeneity test<0.10, otherwise the fixed-effect model was used. ^b Egger's test to evaluate publication bias. P –value <0.05 is considered statistically significant. ^c P-value <0.1 is considered statistically significant for Q statistics. ^{d and e} The results of Asian samples after exclusion of Tan's study. OR: Odds ratio; CI: confidence interval.</p